In 2021, sales improved from KEUR 162,944 to KEUR 188,178 (+15.5%). The “Healthcare Software” division increased its sales from KEUR 154,613 to KEUR 181,202 (+17.2%). The international share of total business volume was 45.2% (2020: 45.6%) and amounted to KEUR 85,134 compared to KEUR 74,333 (2020).

The consolidated earnings before interest and taxes (EBIT) rose very sharply by 21.1% to KEUR 24,114 (2020: KEUR 19,915), and EBITA rose by 18.9% from KEUR 24,284 (2020) to KEUR 28,872. EBITDA increased by 11.3% to KEUR 40,770 (2020: KEUR 36,640), and consolidated surplus increased by 15.7% to KEUR 17,459 (2020: KEUR 15,091).

Operating cash flow increased by 1.4% to KEUR 31,386 (2020: KEUR 30,947) and remains at a very high level. At the end of 2021, the company had cash resources at its disposal in the amount of KEUR 26,172 (31/12/2020: KEUR 26,449). Nexus AG had equity capital amounting to KEUR 142,403 as of 31/12/2021 (31/12/2020: KEUR 123,583). Consequently, the equity capital rate is 57.6% (31/12/2020: 55.4%). This demonstrates that Nexus AG has a sustainable and healthy balance sheet as well as sufficient capital for further financing of its European growth strategy. 

At the annual general meeting on 29/04/2022, the Supervisory Board and the Executive Board will propose to pay a dividend of EUR 0.20 per share.